Pfizer lowers earnings guidance despite a solid Q1
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
May 3, 2022
The pharmaceutical giant still lowered its full-year EPS guidance.
Shares of Pfizer Inc are still down more than 10% for the year.
Shares of Pfizer Inc (NYSE: PFE) are slightly up this morning after the pharmaceutical giant reported market-beating results for its fiscal Q1 on strong sales of its COVID treatments.
Pfizer Q1 financial highlights
Net income printed at $7.864 billion that translates to $1.37 a share.In Q1 last year, net income was capped at $4.877 billion (86 cents a share).On an adjusted basis, per-share earnings stood at $1.62 in the first quarter.$25.661 billion in revenue was up 77%, as per the earnings press release.FactSet consensus was for $1.49 in adjusted EPS and $24.099 billion in revenue.COVID vaccine brought in $13.2 billion, up more than 300% year-over-year.Paxlovid (oral COVID antiviral) sales climbed to $1.50 billion in the recent quarter.
Future outlook and CEO’s remarks
Pfizer reiterated its full-year guidance on Tuesday for $98 billion to $102 billion in revenue. In comparison, analysts had called for a higher $105.9 billion instead. The American multinational lowered its expectations for adjusted EPS to between $6.25 and $6.45.
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
COVID vaccine and Paxlovid is seen bringing in $32 billion and $22 billion in revenue, respectively. In the earnings press release, CEO Albert Bourla said:
We continue to supply the world with Comirnaty and are on track to fulfil our commitment to deliver at least 2 billion doses to low- and middle-income countries in 2021, and 2022, including at least 1 billion this year. In addition, we’re delivering on our production commitments for Paxlovid.
Pfizer Inc stock is still down more than 10% for the year.
68% of retail CFD accounts lose money
Health & pharmaceuticals
Stocks & Shares